Datasheet

Anti-Bevacizumab monoclonal antibody, clone 2C8-13

Catalog Number: MAB11128

Regulatory Status: For research use only (RUO)

Product Description: Mouse monoclonal antibody raised against F(ab)2 fragment of Bevacizumab. Target gene is VEGFA.

Clone Name: 2C8-13

Immunogen: F(ab)2 fragment of Bevacizumab.

Host: Mouse

Applications: Blocking, ELISA
(See our web site product page for detailed applications information)

Protocols: See our web site at http://www.abnova.com/support/protocols.asp or product page for detailed protocols

Specificity: Bevacizumab. This antibody is able to interfere the binding between Bevacizumab and VEGF.

Form: Liquid

Purification: Protein G purification

Isotype: IgG1

Recommend Usage: ELISA (2 ug/mL for coating)
The optimal working dilution should be determined by the end user.

Storage Buffer: In TBS, pH 8.0 (0.09% sodium azide).

Storage Instruction: Store at 4°C for at least 12 months. For long term storage store at -80°C. Aliquot to avoid repeated freezing and thawing.

Entrez GeneID: 7422

Gene Symbol: VEGFA

Gene Alias: MGC70609, VEGF, VEGF-A, VPF

Gene Summary: This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms. [provided by RefSeq]

References:
